Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH)

Fig. 1

a Quantitative assessment of SARS-CoV-2 Spike Antibody levels in people living with HIV who attended Visit 2 (2 weeks [+1 week window) post-second BNT162b2 COVID-19 vaccination series) and Visit 3 (6 months [± 2 weeks] post-primary BNT162b2 COVID-19 vaccination series) (n= 12). Two patients had significantly higher antibody levels at Visit 3, compared to Visit 2. b Quantitative assessment of SARS-CoV-2 Spike Antibody levels in people living with HIV (n= 26) at Visit 3 (6 months [± 2 weeks] post-primary BNT162b2 COVID-19 vaccination series)

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us